Biotech

All Articles

Ascendis' dwarfism medicine smash hits in period 3, endangers BioMarin

.Ascendis Pharma has become a prospective threat to BioMarin's Voxzogo, reporting stage 3 growth pro...

Despite ph. 3 miss out on, Alkeus finds road ahead of time for eye condition resource

.Though Alkeus Pharmaceuticals' oral eye health condition resource failed to significantly reduce ge...

Kairos goes social with $6M IPO to cash trials of cancer drug

.Along with a triad of biotechs attacking the Nasdaq on Friday, it was actually simple to miss a sma...

Vaccine as well as Keytruda combination reliable in squamous tissue cancer

.Immune gate inhibitors are the superheroes of cancer cells treatment. Medicines like Bristol Myers ...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our summary of notable management hirings, firings and also ...

Regeneron's Opdualag opponent presents 57% feedback rate

.Regeneron is actually back along with lasting follow-up for its own LAG-3 prevention and PD-1 preve...

AstraZeneca articles information on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared a very early examine the functionality of its in-house antibody-dru...

iTeos- GSK's TIGIT superstar reveals significant remodeling

.After revealing a phase 3 launch based upon favorable midstage end results, iTeos and GSK are actua...

More joint FDA can accelerate unusual illness R&ampD: document

.The FDA ought to be a lot more available and joint to release a surge in commendations of unusual a...

Zenas, MBX, Bicara scalp to Nasdaq in warm time for biotech IPOs

.It's an uncommonly busy Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bicara Therapeu...